{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.5","value":"4.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"308"}],"units":"Participants"}],"description":"Mean (STD) among patients achieving complete remission (CR) and partial remission (PR)\n\nMyeloma Response Definitions - Using International Uniform Response Criteria:\n\nComplete Response (CR):\n\n* Absence of the original monoclonal paraprotein\n* \\<5% plasma cells in a bone marrow aspirate and also on trephine bone biopsy\n* No increase in size or number of lytic bone lesions\n* Disappearance of soft tissue plasmacytomas.\n\nPartial Response (PR):\n\n* Greater than or equal to 50% reduction in the level of the serum monoclonal paraprotein and/or reduction in 24 hour urinary monoclonal paraprotein either by greater than or equal to 90% or to \\<200 mg/24 hours in light chain disease.\n* If the only measurable non-bone marrow parameter is FLC, greater than or equal to 50% reduction in the difference between involved and uninvolved FLC levels or a 50% decrease in level","dispersionType":"Standard Deviation","groups":[{"description":"Patients receiving peripheral blood stem cell mobilization, chemotherapy (cyclophosphamide + Mesna, growth factor (Granulocyte-colony stimulating factor) and autologous Peripheral Blood Stem Cell transplant with high dose melphalan (200 mg/m\\^2). Post-transplant maintenance therapy is then prescribed if appropriate.","id":"OG000","title":"Chemotherapy and Transplant Treatment"}],"paramType":"MEAN","populationDescription":"55 patients were not evaluable Data was not available on everyone for this endpoint so could not evaluate all 363 patients","reportingStatus":"POSTED","timeFrame":"12 months post transplant","title":"Time to Attainment of CR+PR","type":"SECONDARY","unitOfMeasure":"months"}